Andere talen TaiMed Biologics Inc.

Aandelen

4147

TW0004147004

Biotechnologie & Medisch Onderzoek

Slotkoers Taipei Exchange Andere beurzen 21-04-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
75,30 ^TWD	-3,46%		+2,03%	-12,44%

14/03	TaiMed Biologics Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2024	CI
13/03	TaiMed Biologics Inc. presenteert gegevens van de PROMISE-US studie met Ibalizumab op de CROI	CI

Andere talen

TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	14/03
TaiMed Biologics Inc. Presents Data from the PROMISE-US Trial of Ibalizumab at CROI	13/03
Taimed Biologics Inc. Presents Late-Breaking Phase Iiadata At Croi 2025 on Long-Acting Tmb-365/Tmb-380 Regimenfor Hiv Maintenance Therapy	12/03
TaiMed Biologics Inc. Announces Phase 2A Clinical Study Results of Long-Acting TMB-365/TMB-380 Combination Therapy Have Been Accepted to Present at CROI 2025 Annual Conference	21/01
Taimed Biologics Announces Its Long-Acting Tmb-365/380 Monoclonal Antibody Combination Hiv Therapy Meets All Primary Endpoints in Phase 2A Clinical Study	07/01
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	13/11
TaiMed Biologics Inc. Secures its First CDMO Contract from an International Client	29-10-24
Taimed Biologics Inc. Receives Patent Approval from China for Improving the Pharmacokinetic Performance of Tmb-365 Using Histidine Modification Technology	26-10-24
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	14-08-24
TaiMed Biologics Inc. Receives Patent Approval from the US PTO for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology	18-07-24
Orient Europharma Co., Ltd. Signs an Exclusive Sales and Marketing Agreement for the New AIDS Drug Trogarzo in Taiwan with Taimed Biologics	20-05-24
TaiMed Biologics Inc. and Orient EuroPharma Company Limited Signs Trogarzo Commercial License Agreement in Taiwan	20-05-24
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14-05-24
TaiMed Biologics Inc. Announces Enrollment of the Last Patient in Phase 2a Study of the Long-Acting TMB-365/TMB-380 Mabcombination for the Bi-Monthly Maintenance HIV Therapy	10-05-24
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20-03-24
Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region	13-03-24
Taimed Announces Its Marketing Partner Received Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from the US FDA	28-02-24
TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology	21-02-24
TaiMed Biologics Inc. Announces US FDA Grants Fast Track Designation to TMB-365/TMB-380 Long-Acting Combination Therapy for HIV Infection	07-02-24
TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection	21-12-23
Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo	13-12-23
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14-11-23
Theratechnologies Reports Results from Trogarzo Intramuscular Administration Study; Tesamorelin Poster Presentation	13-10-23
TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study	13-10-23
TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution	06-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen TaiMed Biologics Inc.

Aandelen

4147

TW0004147004

Biotechnologie & Medisch Onderzoek

Andere talen

Filters